387 related articles for article (PubMed ID: 17111715)
1. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
Leibovici D; Lindner A; Stay K; Zisman A
Harefuah; 2006 Oct; 145(10):763-7, 781, 780. PubMed ID: 17111715
[TBL] [Abstract][Full Text] [Related]
2. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
3. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
4. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease.
Klotz LH
Can J Urol; 2005 Feb; 12 Suppl 1():53-7; discussion 101-2. PubMed ID: 15780167
[TBL] [Abstract][Full Text] [Related]
5. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
6. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
[TBL] [Abstract][Full Text] [Related]
7. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
[TBL] [Abstract][Full Text] [Related]
8. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
Klotz L
Eur Urol; 2005 Jan; 47(1):16-21. PubMed ID: 15582244
[TBL] [Abstract][Full Text] [Related]
9. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
[TBL] [Abstract][Full Text] [Related]
10. Conventional treatments of localized prostate cancer.
Zerbib M; Zelefsky MJ; Higano CS; Carroll PR
Urology; 2008 Dec; 72(6 Suppl):S25-35. PubMed ID: 19095125
[TBL] [Abstract][Full Text] [Related]
11. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis.
Klotz LH; Nam RK
Can J Urol; 2006 Feb; 13 Suppl 1():48-55. PubMed ID: 16526983
[TBL] [Abstract][Full Text] [Related]
12. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
13. Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer.
Klotz L
Nat Clin Pract Urol; 2005 Mar; 2(3):136-42; quiz 1 p following 149. PubMed ID: 16474710
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
15. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
[TBL] [Abstract][Full Text] [Related]
16. Active surveillance for good risk prostate cancer: rationale, method, and results.
Klotz LH
Can J Urol; 2005 Jun; 12 Suppl 2():21-4. PubMed ID: 16018828
[TBL] [Abstract][Full Text] [Related]
17. Critical review: is watchful waiting a viable management option for older men with prostate cancer?
Bailey DE; Wallace M
Am J Mens Health; 2007 Mar; 1(1):18-28. PubMed ID: 19482780
[TBL] [Abstract][Full Text] [Related]
18. Expectant management with selective delayed intervention for favorable-risk prostate cancer.
Klotz LH; Choo R; Morton G; Danjoux C
Can J Urol; 2002 Jun; 9 Suppl 1():2-7. PubMed ID: 12121587
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer: epidemiology and health-related quality of life.
Penson DF; Rossignol M; Sartor AO; Scardino PT; Abenhaim LL
Urology; 2008 Dec; 72(6 Suppl):S3-11. PubMed ID: 19095126
[TBL] [Abstract][Full Text] [Related]
20. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression.
Dall'Era MA; Konety BR
Nat Clin Pract Urol; 2008 May; 5(5):277-83. PubMed ID: 18285752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
